PD-L1 Expression as Predictive Biomarker in Patients with NSCLC: A Pooled Analysis

被引：0
|
作者：
Passiglia, Francesco [1 ]
Bronte, Giuseppe [1 ]
Rizzo, Sergio [1 ]
Galvano, Antonio [1 ]
Sortino, Giovanni [1 ]
Musso, Emmanuela [1 ]
Listi, Angela [1 ]
Barraco, Nadia [1 ]
Castiglia, Marta [1 ]
Calo, Valentina [1 ]
Bazan, Viviana [1 ]
Cicero, Giuseppe [1 ]
Rolfo, Christian [2 ]
Russo, Antonio [1 ]
机构：
[1] Palermo Univ Hosp, Dept Surg Oncol & Oral Sci, Med Oncol Unit, Palermo, Italy
[2] Dept Med Oncol, Phase Early Clin Trials Unit 1, Edegem, Belgium
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Immunotherapy; PD-L1; expression; Predictive biomarker; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL31.01
引用
收藏
页码：S232 / S233
页数：2
相关论文
共 50 条
  • [1] PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
    Passiglia, Francesco
    Bronte, Giuseppe
    Bazan, Viviana
    Natoli, Clara
    Rizzo, Sergio
    Galvano, Antonio
    Listi, Angela
    Cicero, Giuseppe
    Rolfo, Christian
    Santini, Daniele
    Russo, Antonio
    ONCOTARGET, 2016, 7 (15) : 19738 - 19747
  • [2] PD-L1 expression as a potential predictive biomarker
    Fusi, Alberto
    Festino, Lucia
    Botti, Gerado
    Masucci, Giuseppe
    Melero, Ignacio
    Lorigan, Paul
    Ascierto, Paolo A.
    LANCET ONCOLOGY, 2015, 16 (13): : 1285 - 1287
  • [3] An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Santoro, Ilka
    Tadokoro, Hakaru
    Barreto, Carmelia
    Oliveira, Pedro
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S245 - S245
  • [4] The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis
    Aguiar, Pedro, Jr.
    Lopes, Gilberto
    Santoro, Ilka
    Tadokoro, Hakaru
    Barreto, Carmelia
    De Mello, Ramon
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S171 - S172
  • [5] Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
    John, Nikolaus
    Schlintl, Verena
    Sassmann, Teresa
    Lindenmann, Joerg
    Fediuk, Melanie
    Wurm, Robert
    Douschan, Philipp
    Zacharias, Martin
    Kalson, Lipika
    Posch, Florian
    Absenger, Gudrun
    Brcic, Luka
    Jost, Philipp J.
    Terbuch, Angelika
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [6] PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
    Patel, Sandip Pravin
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (04) : 847 - 856
  • [7] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [8] Neutrophil PD-L1 expression as a novel predictive biomarker for IV stage melanoma patients
    Cristinziano, Leonardo
    Modestino, Luca
    Della Monica, Carmela
    Capone, Marilena
    Madonna, Gabriele
    Mallardo, Domenico
    Loffredo, Stefania
    Ferrara, Anne Lise
    Vanella, Vito
    Ascierto, Paolo Antonio
    Marone, Gianni
    Galdiero, Maria Rosaria
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 405 - 405
  • [9] Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials
    Vallejo, Jonathon
    Singh, Harpreet
    Larkins, Erin
    Drezner, Nicole
    Ricciuti, Biagio
    Mishra-Kalyani, Pallavi
    Tang, Shenghui
    Beaver, Julia A.
    Awad, Mark M.
    ONCOLOGIST, 2024, : 422 - 430
  • [10] Delta-He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD-1/PD-L1 Inhibitors
    Hong, Green
    Lee, Song-, I
    Kang, Da Hyun
    Chung, Chaeuk
    Park, Hee Sun
    Lee, Jeong Eun
    CANCER MEDICINE, 2025, 14 (07):
12345